FrancophonIA/ELRC3.0 huggingface dataset:
English: For more information about treatment with Mycophenolate mofetil Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Mycophenolate mofetil Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For heart transplants, the recommended adult dose is 1.5 g twice a day, starting within five days following the transplant.
Estonian: Südame siirdamise korral on soovitatav annus täiskasvanutele 1,5 g kaks korda ööpäevas, manustamist tuleb alustada 5 ööpäeva jooksul pärast siirdamist.
English: Mycophenolate mofetil Teva mycophenolate mofetil
Estonian: Mycophenolate mofetil Teva mükofenolaatmofetiil
English: The CHMP concluded that, in accordance with EU requirements, Mycophenolate mofetil Teva has been shown to have comparable quality and to be bioequivalent to CellCept.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Mycophenolate mofetil Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga CellCept.
English: Because Mycophenolate mofetil Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Mycophenolate mofetil Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mycophenolate mofetil Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This means that Mycophenolate mofetil Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called CellCept.
Estonian: See tähendab, et Mycophenolate mofetil Teva on sarnane võrdlusravimiga CellCept, millel juba on Euroopa Liidus müügiluba.
English: The full EPAR for the reference medicine can also be found on the EMEA's website.
Estonian: Euroopa avaliku hindamisaruande täistekst võrdlusravimi kohta on samuti Euroopa Ravimiameti veebilehel.
English: The Committee recommended that Mycophenolate mofetil Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Mycophenolate mofetil Teva müügiloa.
English: In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase'.
Estonian: See muundub organismis mükofenoolhappeks, mis blokeerib ensüümi inosiinmonofosfaatdehüdrogenaasi.
English: This is a summary of the European public assessment report (EPAR) for Mycophenolate mofetil Teva.
Estonian: See on ravimi Mycophenolate mofetil Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: For liver transplants in adults, mycophenolate mofetil should be given as an infusion (drip into a vein) for the first four days after the transplant, before the patient is switched to 1.5 g Mycophenolate mofetil Teva twice a day as soon as it can be tolerated.
Estonian: Maksa siirdamise korral täiskasvanutele manustatakse mükofenolaatmofetiili infusioonina (veeni tilgutamine) esimesel neljal päeval pärast siirdamist ning seejärel 1,5 g kaks korda ööpäevas, niipea kui patsient seda annust talub.
English: Mycophenolate mofetil Teva treatment should be initiated and maintained by a qualified transplant specialist.
Estonian: Ravi Mycophenolate mofetil Tevaga peab alustama ja läbi viima pädev elundisiirdamise eriarst.
English: Other information about Mycophenolate mofetil Teva
Estonian: Muu teave Mycophenolate mofetil Teva kohta
English: The way that Mycophenolate mofetil Teva should be given and the dose depend on the type of organ transplant and the patient's age and size.
Estonian: Mycophenolate mofetil Teva manustamisviis ja annus sõltuvad siiratud elundist ning patsiendi vanusest, pikkusest ja kaalust.
English: Therefore, the CHMP's view was that, as for CellCept, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu CellCepti korral, ületab Mycophenolate mofetil Teva kasulikkus sellega kaasnevad riskid.
English: Because Mycophenolate mofetil Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, CellCept.
Estonian: Et Mycophenolate mofetil Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Mycophenolate mofetil Teva bioekvivalentsust võrdlusravimiga CellCept.
English: What is Mycophenolate mofetil Teva?
Estonian: Mis on Mycophenolate mofetil Teva?
English: Mycophenolate mofetil Teva is a medicine containing the active substance mycophenolate mofetil.
Estonian: Mycophenolate mofetil Teva on ravim, mis sisaldab toimeainena mükofenolaatmofetiili.
English: Mycophenolate mofetil Teva is a ‘generic medicine'.
Estonian: Mycophenolate mofetil Teva on geneeriline ravim.
English: Why has Mycophenolate mofetil Teva been approved?
Estonian: Miks Mycophenolate mofetil Teva heaks kiideti?
English: The active substance in Mycophenolate mofetil Teva, mycophenolate mofetil, is an immunosuppressive medicine.
Estonian: Mycophenolate mofetil Teva toimeaine mükofenolaatmofetiil on immunosupressant.
English: By preventing the production of new DNA, Mycophenolate mofetil Teva reduces the rate at which the lymphocytes multiply.
Estonian: Uue DNA moodustumist pärssides aeglustab Mycophenolate mofetil Teva lümfotsüütide paljunemist.
English: Mycophenolate mofetil Teva is used to prevent the body from rejecting a transplanted kidney, heart or liver.
Estonian: Mycophenolate mofetil Tevat kasutatakse siiratud neeru, südame või maksa äratõukereaktsiooni ennetamiseks.
English: How has Mycophenolate mofetil Teva been studied?
Estonian: Kuidas Mycophenolate mofetil Tevat uuriti?
English: How is Mycophenolate mofetil Teva used?
Estonian: Kuidas Mycophenolate mofetil Tevat kasutatakse?
English: What is Mycophenolate mofetil Teva used for?
Estonian: Milleks Mycophenolate mofetil Tevat kasutatakse?
English: The maximum dose is 600 mg per day.
Estonian: Suurim annus on 600 mg ööpäevas.
English: Stopping treatment with Pregabalin Sandoz should also be done gradually, over at least a week.
Estonian: Ka ravi lõpetamine Pregabalin Sandozega peab toimuma järk-järgult, vähemalt nädala jooksul.
English: Pregabalin Sandoz is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Estonian: Pregabalin Sandozt turustatakse kapslitena (25, 50, 75, 100, 150, 200, 225 ja 300 mg) ja see on retseptiravim.
English: The full EPAR and risk management plan summary for Pregabalin Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pregabalin Sandoze kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in pain, epilepsy and anxiety.
Estonian: See vähendab peaaju ja seljaaju närvirakkude elektrilist talitlust, vähendades nii teiste neurotransmitterite vabanemist, mis tekitavad valu, epilepsiat ja ärevust.
English: • epilepsy, where it is used as an ‘add-on' to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
Estonian: • epilepsia, mille korral seda ravimit kasutatakse lisaks olemasolevale ravile patsientidel, kelle partsiaalsed (aju teatud osas algavad) epilepsiahood ei ole allunud senisele ravile;
English: A risk management plan has been developed to ensure that Pregabalin Sandoz is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pregabalin Sandoze võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pregabalin Sandoz?
Estonian: Mis meetmed võetakse, et tagada Pregabalin Sandoze ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Sandoz on 19 June 2015.
Estonian: Euroopa Komisjon andis Pregabalin Sandoze müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. juunil 2015.
English: Doctors may need to lower the dose in patients who have kidney problems.
Estonian: Neeruprobleemidega patsientidel võib olla vaja kasutada väiksemaid annuseid.
English: Pregabalin Sandoz pregabalin
Estonian: Pregabalin Sandoz pregabaliin
English: The recommended starting dose is 150 mg per day, divided into two or three doses.
Estonian: Soovitatav algannus on 150 mg ööpäevas, mis jagatakse kaheks kuni kolmeks annuseks.
English: After three to seven days, the dose can be increased to 300 mg per day.
Estonian: Kolme kuni seitsme päeva möödudes võib ravimi ööpäevast annust suurendada 300 mg-ni. Annust võib suurendada kuni kaks korda kuni efektiivseima annuse saavutamiseni.
English: The active substance in Pregabalin Sandoz, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Estonian: Pregabalin Sandoze toimeaine pregabaliin sarnaneb struktuurilt organismi looduslikule neurotransmitterile gamma-aminobutüürhappele (GABA), kuid on teistsuguse bioloogilise toimega.
English: The Committee recommended that Pregabalin Sandoz be approved for use in the EU.
Estonian: Komitee soovitas Pregabalin Sandoze kasutamise Euroopa Liidus heaks kiita.
English: Pregabalin Sandoz is a medicine used to treat adults with the following conditions:
Estonian: Pregabalin Sandoz on ravim, mida kasutatakse järgmiste haigusseisundite ravimiseks täiskasvanutel:
English: What is Pregabalin Sandoz and what is it used for?
Estonian: Mis on Pregabalin Sandoz ja milleks seda kasutatakse?
English: Because Pregabalin Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pregabalin Sandoz on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Pregabalin Sandoz is a ‘generic medicine'.
Estonian: Pregabalin Sandoz on geneeriline ravim.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz has been shown to have comparable quality and to be bioequivalent to Lyrica.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Pregabalin Sandoze võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pregabalin Sandoze omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This means that Pregabalin Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
Estonian: See tähendab, et Pregabalin Sandoz on sarnane võrdlusravimiga Lyrica, millel juba on Euroopa Liidus müügiluba.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz.
Estonian: See on ravimi Pregabalin Sandoz Euroopa avaliku hindamisaruande kokkuvõte.
English: For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pregabalin Sandoze kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab Pregabalin Sandoze kasulikkus sellega kaasnevad riskid.
English: It is not intended to provide practical advice on how to use Pregabalin Sandoz.
Estonian: Hindamisaruandes ei anta Pregabalin Sandoze kasutamise praktilisi nõuandeid.
English: Why is Pregabalin Sandoz approved?
Estonian: Miks Pregabalin Sandoz heaks kiideti?
English: For more information about treatment with Pregabalin Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pregabalin Sandozega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because Pregabalin Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica.
Estonian: Et Pregabalin Sandoz on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Pregabalin Sandoze bioekvivalentsust võrdlusravimiga Lyrica.
English: Other information about Pregabalin Sandoz
Estonian: Muu teave Pregabalin Sandoze kohta
English: Pregabalin Sandoz contains the active substance pregabalin.
Estonian: Pregabalin Sandoz sisaldab toimeainena pregabaliini.
English: How does Pregabalin Sandoz work?
Estonian: Kuidas Pregabalin Sandoz toimib?
English: How has Pregabalin Sandoz been studied?
Estonian: Kuidas Pregabalin Sandozt uuriti?
English: How is Pregabalin Sandoz used?
Estonian: Kuidas Pregabalin Sandozt kasutatakse?
English: What are the benefits and risks of Pregabalin Sandoz?
Estonian: Milles seisneb Pregabalin Sandoze kasulikkus ja mis riskid ravimiga kaasnevad?
English: EU/1/18/1269/001 Alpivab
Estonian: EL/1/18/1269/001 Alpivab
English: 20ml (10 mg/ml) 3 vials
Estonian: 20 ml (10 mg/ml) 3 viaali
English: Intravenous use vial (glass)
Estonian: Intravenoosne Klaasviaal
English: MA (EU) number
Estonian: Müügiloa nr Euroopa Liidus Väljamõeldud nimetus
English: Annex I List of nationally authorised medicinal products
Estonian: I lisa Riiklikult heakskiidetud ravimite loetelu
English: HEALTHCARE, PRODUTOS PARA A SAÚDE E HIGIENE, LDA
Estonian: GLAXOSMITHKLINE CONSUMER HEALTHCARE, PRODUTOS PARA A SAÚDE E HIGIENE, LDA
English: ACTAVIS GROUP HF.
Estonian: ACTAVIS GROUP HF. PINEX RETARD
English: PARATABS RETARD PARACETAMOL 500MG TABLET
Estonian: PARATABS RETARD PARATSETAMOOL 500 MG TABLETID
English: PARACETAMOL 650MG TABLET, TRAMADOL 75MG TABLET
Estonian: PARATSETAMOOL 650 MG TABLETID, TRAMADOOL 75 MG TABLETID
English: PANADOL RETARD 8 STUNDEN, 665 MG TABLETTE MIT VERÄNDERTER WIRKSTOFFFREISETZU NG PARACETAMOL
Estonian: STUNDEN, 665 MG TABLETTE MIT VERÄNDERTER WIRKSTOFFFREISETZUNG PARACETAMOL
English: PANADOL RETARD 8 HEURES, 665 MG COMPRIMÉ À LIBÉRATION MODIFIÉE
Estonian: HEURES, 665 MG COMPRIMÉ À LIBÉRATION MODIFIÉE
English: PINEX RETARD
Estonian: PANADOL RETARD 8
English: FORÐATÖFLUR
Estonian: PANODIL EXTEND
English: [the below currently approved indications should be deleted (specific wording of the indication may vary from product to product)]
Estonian: 4.1 Näidustused [allpool toodud praegu heakskiidetud näidustused tuleks kustutada (konkreetse näidustuse sõnastus võib ravimitel erineda)]
English: • Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)
Estonian: • Kroonilise patoloogilise kognitiivse ja neurosensoorse häire (välja arvatud Alzheimeri tõbi ja dementsuse teised vormid) sümptomaatiline ravi eakatel.
English: • Ancillary treatment of Raynaud's syndrome
Estonian: • Raynaud' sündroomi toetav ravi
English: • Prophylaxis of migraine headache
Estonian: • Migreeni peavalu profülaktika
English: Annex III Amendments to relevant sections of the summaries of product characteristics and package leaflets
Estonian: Parandused ravimi omaduste kokkuvõtte ja pakendi infolehe vastavates lõikudes
English: • Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin
Estonian: • Eeldatavalt vereringest põhjustatud nägemisteravuse halvenemise ja nägemisvälja häirete toetav ravi
English: • Symptomatic treatment of veno-lymphatic insufficiency All references to the above mentioned indications should be deleted from the remaining relevant sections of the summaries of product characteristics.
Estonian: Ravimi omaduste kokkuvõtte vastavatest lõikudes tuleks kustutada kõik viited ülalmainitud näidustustele.
English: the MAHs should identify a patient population for which the benefit risk ratio of tetrazepam containing medicines is positive on the basis of scientifically relevant supportive data.
Estonian: müügiloa hoidjad peavad teaduslikult usaldusväärsete toetavate andmete alusel kindlaks tegema patsientide populatsiooni, kellel on tetrasepaami sisaldavate ravimite kasu ja riski suhe positiivne.
English: Conditions for lifting the suspension of the marketing authorisations
Estonian: Müügilubade peatamise tühistamise tingimused
English: For the suspension to be lifted, the National competent authorities of Member States shall verify that the following conditions are fulfilled by the MAHs:
Estonian: Müügilubade peatamise tühistamiseks peavad riikide pädevad asutused veenduma, et müügiloa hoidjad on täitnud järgmised tingimused:
English: Annex III Conditions for lifting the suspension of the marketing authorisations
Estonian: III lisa Müügilubade peatamise tühistamise tingimused
English: Two clinical trials were carried out under field conditions.
Estonian: Tehti kaks kliinilist uuringut välitingimustes.
English: Zero days
Estonian: Null päeva
English: Not permitted for use in lactating animals producing milk for human consumption
Estonian: Ei ole lubatud kasutada lakteerivatel loomadel, kelle piim on mõeldud inimtarbimiseks
English: Tiludronate belongs to the biphosphonates family.
Estonian: Tiludronaat kuulub bifosfonaatide rühma.
English: Assessment of the efficacy of Tildren
Estonian: Tildreni efektiivsuse hindamine
English: List of the name, pharmaceutical form, strength of the veterinary medicinal product, animal species, route(s) of administration, marketing authorisation holder in the member states
Estonian: Veterinaarravimite nimetuste, ravimvormide, tugevuste, loomaliikide, manustamisviiside ja müügiloa hoidjate loetelu liikmesriikides
English: Consequently, in the absence of any demonstrated benefit of this component the risk-benefit analysis for the product is negative, therefore presenting an unacceptable serious risk to human or animal health or to the environment.
Estonian: Sellest tulenevalt oldi seisukohal, et kuna kõnealuse komponendi kasulikkust ei ole tõendatud, on toote riski ja kasulikkuse analüüsi tulemus negatiivne ja toode seab inim- või loomade tervise või keskkonna vastuvõetamatult tõsise riski olukorda.
English: A disagreement between the Member States on the efficacy of the product was not solved.
Estonian: Liikmesriigid ei jõudnud toote efektiivsuse suhtes ühisele arvamusele.
English: 1 mg/kg body weight (5 ml reconstituted solution per 100 kg)
Estonian: 1 mg kehakaalu kilogrammi kohta (5 ml taastatud lahust 100 kg kohta)
English: Nevertheless the analysis of the Periodic Safety Update Report demonstrated that the number of serious adverse reactions was small and the CVMP concluded that there are no major concerns regarding the safety of the product.
Estonian: Sellele vaatamata näitas perioodiliselt uuendatava ohutusaruande analüüs, et tõsiste kõrvalnähtude arv oli väike ning veterinaarravimite komitee jõudis järeldusele, et toote ohutuses ei ole suuremaid kahtlusi.
English: However, in the assessment for this opinion only those horses suffering from bone spavin and treated with 0.1 mg/kg/day for 10 days are included.
Estonian: Käesoleva arvamuse jaoks tehtud hindamisse kaasati siiski vaid need hobused, kellel oli pätk ja kellele manustati 10 päeva vältel 0,1 mg ravimit kehakaalu kilogrammi kohta ööpäevas.
English: Product invented name
Estonian: Ravimi väljamõeldud nimetus
English: It is common for horses affected by this disease to have reduced performance.
Estonian: Haigust põdevate hobuste suutlikkus on tavaliselt vähenenud.
English: Scientific conclusions and grounds for suspension or refusal of the granting of the marketing authorisation
Estonian: Teaduslikud järeldused ja müügiloa peatamise või müügiloa andmisest keeldumise alused
English: There are considered to be significant deficiencies in the data provided by the Marketing Authorisation Holder in support of the efficacy of product.
Estonian: Leiti, et andmetes, mille müügiloa hoidja esitas toote efektiivsuse toetuseks, esineb olulisi puudujääke.
English: Further, a complementary analysis assessed the percentage of horses with no or minimal lameness and the percentage of horses with normal level of activity.
Estonian: Peale selle hinnati lisaanalüüsi käigus üldse mitte või minimaalselt lonkavate hobuste osakaalu ja tavapärase aktiivsustasemega hobuste osakaalu.
English: In the view of Belgium and Sweden the clinical trial performed according to the recommended dosage failed to show a statistical significant effect of the product.
Estonian: Vastavalt Belgia ja Rootsi seisukohale ei näidanud soovitusliku annustamisrežiimi alusel tehtud kliiniline uuring toote statistiliselt olulist mõju.
English: Applicant or Marketing Authorisation Holder
Estonian: Liikmesriik Müügiloa taotleja või hoidja
English: Tildren 500 mg lyophilisate for solution for infusion
Estonian: Tildren 500 mg lüofilisaat infusioonilahuse jaoks
English: Such lesions in the hock joint are responsible for varying degrees of lameness, often with an insidious onset, and leading to a complete ankylosis of the affected joints in the later stages of the disease.
Estonian: Need kahjustused kannaliigeses põhjustavad erineva raskusastmega lonkamist, mis algab sageli märkamatult, ning viivad haiguse hilisemates staadiumides haigete liigeste täieliku anküloosini.
English: With regard to the influence of exercise, the MAH concluded that the variation in exercise had been controlled to avoid any influence on the objective evaluation of the effect of the Tildren treatment.
Estonian: Harjutuste mõju osas jõudis müügiloa hoidja järeldusele, et harjutuste varieerumine oli kontrolli all, et vältida mis tahes mõju Tildrenil põhineva ravi efektiivsuse objektiivsele hindamisele.
English: As bone resorption and bone formation are two coupled processes responsible for the integrity of bone mechanical properties, the inhibition of resorption secondarily leads to a slow-down in bone formation and, consequently, to a slow down in remodelling.
Estonian: Et luu resorptsioon ja luu moodustumine on kaks teineteisega seotud protsessi, millest sõltub luu mehaaniliste omaduste ühtsus, toob resorptsiooni pärssimine sekundaarselt kaasa luu moodustumise aeglustumise ja sellest tulenevalt luu ümberkujundamise aeglustumise.
English: Grounds for refusal of the granting of the marketing authorisation
Estonian: Müügiloa andmisest keeldumise põhjendused
English: Tiludronate is incorporated into the bone matrix and the osteoclasts where it affects ATP-dependent intracellular enzymes leading to apoptosis.
Estonian: Tiludronaat inkorporeeritakse luumaatriksisse ja osteoklastidesse, kus see mõjutab ATP-sõltuvaid rakusiseseid ensüüme, põhjustades apoptoosi.
English: The data demonstrate a treatment effect on lameness whereas the role of exercise in connection with treatment was considered unresolved.
Estonian: Uuringu andmed näitavad, et ravi avaldab lonkamisele mõju, samas kui harjutuste roll seoses raviga jääb ebaselgeks.
English: The dose of 1 mg/kg was selected as the dose producing approximately 75 % inhibition of bone resorption.
Estonian: Annus 1 mg kehakaalu kilogrammi kohta valiti seetõttu, et sellega pärsiti luu resorptsiooni umbes 75% ulatuses.